SKB BIO (06990) released its interim results, with shareholders' net profit reaching 388 million yuan, marking a turnaround from loss to profit compared to the same period last year.

19:16 17/08/2026

Kelo-Biotai Biological (06990) announced its interim results for the six months ended June 30, 2026. During this period, the group achieved revenue of 978 million yuan (RMB, the same below), an increase of 2.93% year-on-year; gross profit of 737 million yuan, an increase of 11.65% year-on-year; and a profit attributable to shareholders of 388 million yuan, turning losses into profits year-on-year; basic earnings per share were 1.6639 yuan.

SKB BIO (06990) announced its interim results for the six months ended June 30, 2026, during which the group achieved revenue of 978 million yuan (RMB, the same below), an increase of 2.93% year-on-year; gross profit of 737 million yuan, an increase of 11.65% year-on-year; and a profit attributable to shareholders of 388 million yuan, reversing from loss to profit year-on-year; basic earnings per share of 1.6639 yuan. The announcement stated that the increase in revenue during the period was mainly due to a rise in pharmaceutical sales, which contributed 657 million yuan to the revenue.

CHINAGOLDINTL (02099): The slope management plan for Changshanhao Mine has been approved, and mining operations are expected to resume.

From the perspective of garlic-scented village life, we see how PDD Holdings Inc. Sponsored ADR Class A (PDD.US) empowers rural areas through its practice of "free delivery to villages," injecting fresh vitality into the economy.

GUOTAI JUNAN I (01788) has appointed Haode Financing as its independent financial advisor.

CHINAGOLDINTL (02099): The slope management plan for Changshanhao Mine has been approved, and mining operations are expected to resume.

GUOTAI JUNAN I (01788) has appointed Haode Financing as its independent financial advisor.